For this purpose the multi-receptor tyrosine kinase inhibitors, sorafenib and sunitinib, were used at concentrations that are known to inhibit proliferation of cancer cells including bladder cancer (J82) cells [30-32]. The gene discussed is NTRK1; the disease is urinary bladder cancer.